Successful Treatment of Refractory Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis (SAPHO) Syndrome with Baricitinib, a Janus Kinase Inhibitor

Jianqiu Yang,1,2 Chunyu Yuan,1 Shengru Zhou,1 Zhicheng Teng,2 Min Li1 1Department of Dermatology, Dushu Lake Hospital Affiliated to Soochow University (Medical Center of Soochow University), Suzhou, People’s Republic of China; 2Suzhou Medical College of Soochow University, Suzhou, People’s Republic...

Full description

Bibliographic Details
Main Authors: Yang J, Yuan C, Zhou S, Teng Z, Li M
Format: Article
Language:English
Published: Dove Medical Press 2024-03-01
Series:Clinical, Cosmetic and Investigational Dermatology
Subjects:
Online Access:https://www.dovepress.com/successful-treatment-of-refractory-synovitis-acne-pustulosis-hyperosto-peer-reviewed-fulltext-article-CCID
_version_ 1797275638418112512
author Yang J
Yuan C
Zhou S
Teng Z
Li M
author_facet Yang J
Yuan C
Zhou S
Teng Z
Li M
author_sort Yang J
collection DOAJ
description Jianqiu Yang,1,2 Chunyu Yuan,1 Shengru Zhou,1 Zhicheng Teng,2 Min Li1 1Department of Dermatology, Dushu Lake Hospital Affiliated to Soochow University (Medical Center of Soochow University), Suzhou, People’s Republic of China; 2Suzhou Medical College of Soochow University, Suzhou, People’s Republic of ChinaCorrespondence: Min Li, Department of Dermatology, Dushu Lake Hospital Affiliated to Soochow University (Medical Center of Soochow University), No. 9, Chongwen Road, Suzhou, 215100, People’s Republic of China, Tel +86-18936140383, Email lm@suda.edu.cnAbstract: Synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome, a rare immune-mediated inflammatory disease, poses diagnostic and therapeutic challenges owing to its multi-system involvement, high heterogeneity, and lack of specific laboratory tests. Additionally, lacking evidence-based treatment recommendations, with the primary approach focusing on symptomatic relief. Herein, we report the case of a 32-year-old Chinese woman who presented with recurrent, generalized multiple osteoarticular pain lasting over one year and skin erythema pustulosis for 11 months. Traditional treatments, including non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, disease-modifying antirheumatic drugs (DMARDs), and other traditional approaches, yielded no significant effects. Despite the prior use of adalimumab and acitretin capsules, the treatment remained unsatisfying, especially regarding the skin lesions. Considering the complex pathogenesis of SAPHO syndrome, the patient was orally administered baricitinib (2 mg), a Janus kinase (JAK) inhibitor, twice daily. A notable improvement in both skin lesions and osteoarticular pain was observed within two weeks of treatment initiation. Subsequently, the dosage of baricitinib was halved and continued for an additional three months, during which regular follow-ups revealed neither disease recurrence nor adverse effects. Collectively, the successful treatment of refractory SAPHO syndrome with baricitinib presents a promising implication for addressing the therapeutic challenges of this rare autoimmune condition, offering a potential breakthrough in managing its complex manifestations.Keywords: SAPHO syndrome, autoinflammatory conditions, therapeutic challenges, baricitinib
first_indexed 2024-03-07T15:17:21Z
format Article
id doaj.art-bdc8737cd0be4a398424e66537e3f39a
institution Directory Open Access Journal
issn 1178-7015
language English
last_indexed 2024-03-07T15:17:21Z
publishDate 2024-03-01
publisher Dove Medical Press
record_format Article
series Clinical, Cosmetic and Investigational Dermatology
spelling doaj.art-bdc8737cd0be4a398424e66537e3f39a2024-03-05T17:51:52ZengDove Medical PressClinical, Cosmetic and Investigational Dermatology1178-70152024-03-01Volume 1752953790881Successful Treatment of Refractory Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis (SAPHO) Syndrome with Baricitinib, a Janus Kinase InhibitorYang JYuan CZhou STeng ZLi MJianqiu Yang,1,2 Chunyu Yuan,1 Shengru Zhou,1 Zhicheng Teng,2 Min Li1 1Department of Dermatology, Dushu Lake Hospital Affiliated to Soochow University (Medical Center of Soochow University), Suzhou, People’s Republic of China; 2Suzhou Medical College of Soochow University, Suzhou, People’s Republic of ChinaCorrespondence: Min Li, Department of Dermatology, Dushu Lake Hospital Affiliated to Soochow University (Medical Center of Soochow University), No. 9, Chongwen Road, Suzhou, 215100, People’s Republic of China, Tel +86-18936140383, Email lm@suda.edu.cnAbstract: Synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome, a rare immune-mediated inflammatory disease, poses diagnostic and therapeutic challenges owing to its multi-system involvement, high heterogeneity, and lack of specific laboratory tests. Additionally, lacking evidence-based treatment recommendations, with the primary approach focusing on symptomatic relief. Herein, we report the case of a 32-year-old Chinese woman who presented with recurrent, generalized multiple osteoarticular pain lasting over one year and skin erythema pustulosis for 11 months. Traditional treatments, including non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, disease-modifying antirheumatic drugs (DMARDs), and other traditional approaches, yielded no significant effects. Despite the prior use of adalimumab and acitretin capsules, the treatment remained unsatisfying, especially regarding the skin lesions. Considering the complex pathogenesis of SAPHO syndrome, the patient was orally administered baricitinib (2 mg), a Janus kinase (JAK) inhibitor, twice daily. A notable improvement in both skin lesions and osteoarticular pain was observed within two weeks of treatment initiation. Subsequently, the dosage of baricitinib was halved and continued for an additional three months, during which regular follow-ups revealed neither disease recurrence nor adverse effects. Collectively, the successful treatment of refractory SAPHO syndrome with baricitinib presents a promising implication for addressing the therapeutic challenges of this rare autoimmune condition, offering a potential breakthrough in managing its complex manifestations.Keywords: SAPHO syndrome, autoinflammatory conditions, therapeutic challenges, baricitinibhttps://www.dovepress.com/successful-treatment-of-refractory-synovitis-acne-pustulosis-hyperosto-peer-reviewed-fulltext-article-CCIDsapho syndromeautoinflammatory conditionstherapeutic challengesbaricitinib
spellingShingle Yang J
Yuan C
Zhou S
Teng Z
Li M
Successful Treatment of Refractory Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis (SAPHO) Syndrome with Baricitinib, a Janus Kinase Inhibitor
Clinical, Cosmetic and Investigational Dermatology
sapho syndrome
autoinflammatory conditions
therapeutic challenges
baricitinib
title Successful Treatment of Refractory Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis (SAPHO) Syndrome with Baricitinib, a Janus Kinase Inhibitor
title_full Successful Treatment of Refractory Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis (SAPHO) Syndrome with Baricitinib, a Janus Kinase Inhibitor
title_fullStr Successful Treatment of Refractory Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis (SAPHO) Syndrome with Baricitinib, a Janus Kinase Inhibitor
title_full_unstemmed Successful Treatment of Refractory Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis (SAPHO) Syndrome with Baricitinib, a Janus Kinase Inhibitor
title_short Successful Treatment of Refractory Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis (SAPHO) Syndrome with Baricitinib, a Janus Kinase Inhibitor
title_sort successful treatment of refractory synovitis acne pustulosis hyperostosis and osteitis sapho syndrome with baricitinib a janus kinase inhibitor
topic sapho syndrome
autoinflammatory conditions
therapeutic challenges
baricitinib
url https://www.dovepress.com/successful-treatment-of-refractory-synovitis-acne-pustulosis-hyperosto-peer-reviewed-fulltext-article-CCID
work_keys_str_mv AT yangj successfultreatmentofrefractorysynovitisacnepustulosishyperostosisandosteitissaphosyndromewithbaricitinibajanuskinaseinhibitor
AT yuanc successfultreatmentofrefractorysynovitisacnepustulosishyperostosisandosteitissaphosyndromewithbaricitinibajanuskinaseinhibitor
AT zhous successfultreatmentofrefractorysynovitisacnepustulosishyperostosisandosteitissaphosyndromewithbaricitinibajanuskinaseinhibitor
AT tengz successfultreatmentofrefractorysynovitisacnepustulosishyperostosisandosteitissaphosyndromewithbaricitinibajanuskinaseinhibitor
AT lim successfultreatmentofrefractorysynovitisacnepustulosishyperostosisandosteitissaphosyndromewithbaricitinibajanuskinaseinhibitor